Comments on: Apple shares rebound on Jobs news
Stock rises after announcement that Steve Jobs will remain as CEO, while recovering from hormone therapy treatment.
Stock rises after announcement that Steve Jobs will remain as CEO, while recovering from hormone therapy treatment.
Web sites launch all the time, but they also shut their doors. We highlight 15 that bit the dust this year.
Let the debate begin: Was the iPhone more important than iTunes? Was anything bigger than Google finding a great business model? CNET offers its list of the 10 most important stories of the '00s.
At the start of the 21st century, there's no tech outfit more influential than Apple. CNET News' Erica Ogg and other reporters will attempt to make sense of the rumors, hype, products, and people that will shape the future of the company. But Apple's not the only game in town, as the established cell phone companies and others strike back against the iPhone. E-mail Erica at erica.ogg@cnet.com.
Add this feed to your online news reader
Which means they're still worth half of what they were seven months ago.
Oh yeah, and the tech markets are about half red/half green just now.
-
by jwilson00m1
January 5, 2009 12:25 PM PST
- If you think about Steve's recent medical history this makes pretty good sense. He thought he was Ok, then found he had pancreatic cancer which has an abysmal survival rate, then he disappears for a bit and comes back looking pretty good then he starts to thin out. If I had to guess, I'd say he had his pancreas removed. Now he's trying to live without one which is possible but hard. He'd have to use an insulin pump our other insulin source such as injections or the new inhaled version, and he'd have to take enzymes that would act like the enzymes that he pancreas puts into the intestine to absorb nutrients (fats and proteins). As you might imagine it is pretty hard to mimic the actions of the pancreas with pills and injections. It is not an enviable position to be in but at least he's not dead.
-
Like this
Reply to this comment
-
(3 Comments)